Curacle Co Ltd (365270)

Currency in KRW
12,080
+2,360(+24.28%)
Closed·
Unusual trading volume
Trading near 52-week High
365270 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9,73012,430
52 wk Range
3,60012,430
Key Statistics
Bid/Ask
12,080.00 / 12,090.00
Prev. Close
9,720
Open
9,730
Day's Range
9,730-12,430
52 wk Range
3,600-12,430
Volume
2.92M
Average Volume (3m)
492.63K
1-Year Change
88.4555%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
365270 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Curacle Co Ltd Company Profile

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer–based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.

Compare 365270 to Peers and Sector

Metrics to compare
365270
Peers
Sector
Relationship
P/E Ratio
−11.7x−7.5x−0.6x
PEG Ratio
6.36−0.140.00
Price/Book
5.2x3.6x2.6x
Price / LTM Sales
179.2x13.9x3.4x
Upside (Analyst Target)
-51.4%44.4%
Fair Value Upside
Unlock7.1%6.1%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-191.00 / --
Revenue / Forecast
7.10M / --
EPS Revisions
Last 90 days

365270 Income Statement

FAQ

What Is the Curacle Co (365270) Stock Price Today?

The Curacle Co stock price today is 12 080

What Stock Exchange Does Curacle Co Trade On?

Curacle Co is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Curacle Co?

The stock symbol for Curacle Co is "365270."

What Is the Curacle Co Market Cap?

As of today, Curacle Co market cap is 253.79B.

What Is Curacle Co's Earnings Per Share (TTM)?

The Curacle Co EPS (TTM) is -1,217.16.

From a Technical Analysis Perspective, Is 365270 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Curacle Co Stock Split?

Curacle Co has split 0 times.

What is the current trading status of Curacle Co (365270)?

As of 30 Jan 2026, Curacle Co (365270) is trading at a price of 12 080, with a previous close of 9 720. The stock has fluctuated within a day range of 9 730 to 12 430, while its 52-week range spans from 3 600 to 12 430.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.